Hyperfine (NASDAQ:HYPR) Issues Earnings Results

Hyperfine (NASDAQ:HYPR) released its earnings results on Monday. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01, Zacks reports. Hyperfine had a negative net margin of 156.42% and a negative return on equity of 87.74%. The firm had revenue of $5.96 million for the quarter, compared to analysts’ expectations of $5.84 million.

Here are the key takeaways from Hyperfine’s conference call:

• Hyperfine reported a record $6.0 million in Q3 revenue, up 73% year over year, with contributions from U.S. hospitals, U.S. offices, and international markets. Gross margin reached a record 56.7%, and revenue grew much faster than operating expenses.
• Operating leverage improved: operating loss narrowed to $7.3 million, while net cash burn fell 29% sequentially to a quarterly low of $5.6 million—below quarterly revenue for the first time. The company ended September with $37.9 million in cash and expects runway into 2028, assuming no additional financing or future debt draws.
• Management reaffirmed 2026 revenue guidance of $20 million–$22 million and net cash burn guidance of $26 million–$28 million, while raising the low end of its gross-margin range to 52.5% from 50%. The revenue outlook was not raised despite the strong quarter; management cited the lumpy nature of capital-equipment sales and a one-time system upgrade that boosted Q4 2025 revenue.
• The company completed enrollment in its Contrast PMR study and remains on track to submit a 510(k) application by year-end 2026; management said clearance could come around Q2 to mid-2027. It expects contrast imaging to broaden use in hospitals and offices, including access to a dedicated reimbursement code in outpatient settings.
• Hyperfine is exploring a brain-health and wellness offering using its existing scanner, with potential software and cloud development rather than major hardware changes. Management characterized this as an emerging opportunity, but does not expect meaningful revenue from it before 2028 or later.

Hyperfine Stock Performance

Shares of NASDAQ HYPR traded up $0.02 during midday trading on Wednesday, hitting $0.70. The company’s stock had a trading volume of 186,287 shares, compared to its average volume of 727,429. The stock has a fifty day moving average price of $0.79 and a 200 day moving average price of $1.11. Hyperfine has a one year low of $0.67 and a one year high of $1.94. The company has a current ratio of 6.15, a quick ratio of 5.45 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $74.02 million, a price-to-earnings ratio of -2.33 and a beta of 1.49.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Wall Street Zen downgraded Hyperfine from a “hold” rating to a “sell” rating in a research note on Sunday. BTIG Research reissued a “buy” rating and issued a $2.00 target price on shares of Hyperfine in a research report on Tuesday, September 22nd. B. Riley Financial restated a “buy” rating and issued a $1.60 target price (down from $2.00) on shares of Hyperfine in a research note on Monday, August 10th. Loop Capital set a $2.00 price target on Hyperfine in a research report on Tuesday, October 27th. Finally, Lucid Cap Mkts assumed coverage on Hyperfine in a research note on Tuesday, October 27th. They set a “strong-buy” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $2.02.

About Hyperfine

Hyperfine, Inc. (NASDAQ: HYPR) is a medical technology company focused on making magnetic resonance imaging more accessible and convenient. The company develops portable, low-field MRI technology designed to bring brain imaging directly to patients in locations such as intensive care units, emergency departments, operating rooms and other point-of-care settings. Hyperfine’s primary product is the Swoop Portable MR Imaging System, a compact MRI platform that can be moved to a patient’s bedside. The system is designed to produce brain images without requiring patients to be transported to a traditional radiology department.